Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation

Breast. 2004 Aug;13(4):347-9. doi: 10.1016/j.breast.2003.11.009.

Abstract

We report on the case of a patient with a diagnosis of a HER2-overexpressing metastatic breast cancer which was refractory to a combination of a Raf kinase inhibitor and docetaxel, but highly sensitive to trastuzumab, a HER2-targeted monoclonal antibody. Interestingly, there was no evidence of Ras-Raf-MAPK or PI3K-Akt pathways activation.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / immunology
  • Drug Resistance, Neoplasm
  • Female
  • Genes, ras
  • Humans
  • Middle Aged
  • Mitogen-Activated Protein Kinase Kinases
  • Phosphatidylinositol 3-Kinases
  • Receptor, ErbB-2 / genetics
  • Trastuzumab
  • Treatment Outcome
  • raf Kinases

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Phosphatidylinositol 3-Kinases
  • Receptor, ErbB-2
  • raf Kinases
  • Mitogen-Activated Protein Kinase Kinases
  • Trastuzumab